TabletsClinical Overview
Clopidogrel and Aspirin is the cornerstone Dual Antiplatelet Therapy (DAPT) on the WHO Model List of Essential Medicines. Aspirin irreversibly acetylates platelet cyclooxygenase-1 (COX-1), blocking thromboxane A2 production, while clopidogrel is an oral thienopyridine prodrug whose active metabolite irreversibly binds to platelet P2Y12 adenosine diphosphate (ADP) receptors, preventing ADP-mediated glycoprotein IIb/IIIa activation. This dual blockade potently inhibits platelet aggregation across complementary pathways. Indicated for acute coronary syndromes (STEMI, NSTEMI, unstable angina) and prevention of subacute stent thrombosis following percutaneous coronary intervention (PCI).
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily with a full glass of water, with or immediately after meals to reduce gastric irritation. Swallow gastro-resistant tablets/capsules whole. Maintain continuous therapy for the exact duration (typically 6-12 months post-stent) specified by the cardiologist.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dyspepsia, bruising, epistaxis, gastrointestinal discomfort, minor bleeding. Rare/Severe: Boxed warning: Major gastrointestinal bleeding, intracranial hemorrhage, thrombotic thrombocytopenic purpura (TTP), and aplastic anemia.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Black box warning: Clopidogrel efficacy depends on metabolic activation by CYP2C19; poor metabolizers have higher rates of stent thrombosis. High bleeding risk; report black tarry stools, unusual bruising, or hematuria immediately. Premature discontinuation drastically increases the risk of fatal stent thrombosis.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified cardiologist/pharmacist before initiating, altering, or substituting any cardiovascular medication.
Aspirin Gastro-resistant Tablets 150 mg
Aspirin Gastro-Resistant Tablets (150mg) is an acetylated salicylate on the WHO Model List of Essential Medicines. It irreversibly acetylates the serine 529 residue of cyclooxygenase-1 (COX-1), permanently suppressing platelet thromboxane A2 (TXA2) generation for the entire lifespan of the platelet (7-10 days). Enteric coating bypasses the stomach to dissolve in the alkaline duodenum, minimizing direct contact gastric mucosal injury. Indicated for secondary prevention of myocardial infarction, ischemic stroke, transient ischemic attacks (TIA), and unstable angina.
Clopidogrel Tablets 75mg
Clopidogrel Bisulphate is an oral thienopyridine P2Y12 platelet inhibitor on the WHO Model List of Essential Medicines. It requires hepatic bioactivation by CYP2C19 to form an active thiol metabolite that irreversibly modifies platelet P2Y12 ADP receptors for the entire 7-10 day lifespan of the platelet, preventing ADP-induced platelet activation and fibrinogen binding. Indicated for secondary prevention of atherothrombotic events in patients with recent myocardial infarction, recent ischemic stroke, or established peripheral arterial disease, and as part of DAPT in acute coronary syndromes.
Atorvastatin 10mg + Clopidogrel 75mg Capsules
Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.
Acetylsalicylic Acid (Aspirin) Gastro-resistant Tablets 325mg
Acetylsalicylic Acid (Aspirin) Gastro-resistant Tablets 325mg is an evidence-based dermatological formulation. It acts by delivering targeted active therapeutic ingredients to cutaneous lesions to relieve skin pathology, restore barrier integrity, and manage dermatoses.